| Olysio (simeprevir) / J&J, Medivir |
NCT01727323 / 2010-021337-31: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 |
|
|
| Active, not recruiting | 3 | 109 | US, Canada, Europe | TMC435, Pegylated interferon alpha-2a, Ribavirin | Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals | Hepatitis C Virus Genotype-1 | 08/13 | 08/13 | | |
NCT02256176 / 2014-003446-27: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection |
|
|
| Not yet recruiting | 3 | 40 | Europe | Simeprevir, TMC435, Sofosbuvir | Janssen R&D Ireland, Janssen R&D Ireland | Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C | 11/15 | 01/16 | | |
NCT05616598: Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters |
|
|
| Completed | 2/3 | 200 | RoW | Sofosbuvir +daclatasvir+ simeprevir+Ribavirin | Benha University | Male Infertility, HCV | 11/22 | 12/22 | | |
| Recruiting | 2 | 160 | RoW | PR4 + LDV/SOF + ASV 4 wk, Pegasys®, Copegus®, Harvoni®, Sunvepra®, PR4 + LDV/SOF + SMV 4 wk, OLYSIO®, PR4 + LDV/SOF + ASV 6 wk, PR4 + LDV/SOF + SMV 6 wk, PR4 + LDV/SOF + ASV 8 wk, PR4 + LDV/SOF + SMV 8 wk, PR4 + LDV/SOF + ASV 12 wk, PR4 + LDV/SOF + SMV 12 wk | Humanity and Health Research Centre, Beijing 302 Hospital, Nanfang Hospital of Southern Medical University | Chronic Hepatitis C Infection | 10/22 | 12/22 | | |
NCT05728619: HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer |
|
|
| Recruiting | 1b/2 | 64 | RoW | HTMC0435, Temozolomide | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Recurrent Extensive Stage Small Cell Lung Carcinoma | 08/24 | 10/24 | | |
CTR20200573: Phase I/II clinical trial evaluating HTMC0435 tablets in patients with advanced malignant solid tumors |
|
|
| Recruiting | 1/2 | 42 | China | HTMC0435 - Shanghai Huilun | Shanghai Huilun Life Technology Co., Ltd./Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Avanced malignant solid tumors | | | | |
| grazoprevir (MK-5172) / Merck (MSD) |
2017-001463-21: MK-3682B in Hepatitis C Virus (HCV) Genotype 3 (GT3) participants |
|
|
| Ongoing | 3 | 426 | Europe | MK-3682B, MK-3682B, Tablet | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | Treatment of hepatitis C virus (HCV) infection, Treatment of chronic hepatitis C virus (HCV) infection, Diseases [C] - Virus Diseases [C02] | | | | |
2016-000620-26: MK-3682B Fixed Dose Combination (FDC) in Subjects with Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Ongoing | 2/3 | 160 | Europe | MK-3682B, MK-3682B, Tablet | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Chronic Hepatitis C Infected Patient, Chronic Hepatitis C Infected Patient, Diseases [C] - Virus Diseases [C02] | | | | |
| Ganovo (danoprevir) / Roche, Ascletis, Pfizer |
ChiCTR2000030000: An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19) |
|
|
| Recruiting | 4 | 50 | | Ganovo/ ritonavir oral ;Pegasys injection ;Novaferon intramuscular injection+Spray inhalation ;Coriolus oral ;TCM+Spray inhalation | Nanchang Ninth Hospital; Nanchang Ninth Hospital, Ascletis Pharmaceuticals CO., LTD. | Pneumonia caused by new coronavirus | | | | |
ChiCTR1800019812: The efficacy and safety of 12-week ritonavir-boosted danoprevir plus pegylated interferon and ribavirin treatment of CHC genotype 1 patients experienced DAA failure: a multi-center, open labeled clinical trial |
|
|
| Not yet recruiting | 4 | 30 | | 12 weeks treatment, 12weeks follow-up | the 2nd affiliated hospital of Chongqing Medical School; Ascletis Pharmaceuticals Co., Ltd., Response by Ascletis Pharmaceuticals Co.,Ltd | HCV | | | | |
ChiCTR2000040851: The pharmacokinetics of single and multiple doses of ASC16 quadruplex administration |
|
|
| Completed | 1 | 64 | | ASC16 (200 mg, 1 tablet) ;ASC08 (100 mg, 1tablet) ;RTV (100 mg, 1tablet) ;RBV (500 mg, 5tablet) ;ASC16 (200 mg, 1 tablet) +ASC08/ R (100 mg/100 mg, 1 tablet /1 tablet) + RBV (500 mg, 5 tablets) ;Group F: ASC16 (200 mg, 1 tablet, QD) + ASC08/ R (100 mg/100 mg, 1 tablet /1 tablet, BID) + RBV (500 mg, 5 tablets, BID) | Nanning Second People's Hospital; Ascletis BioScience Co., Ltd., self-finance | Basic Science | | | | |
ChiCTR2000030259: Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial |
|
|
| Recruiting | N/A | 60 | | Danoprevir sodium tablets,/ritonavir oral ;Symptomatic treatment | Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Ascletis Pharmaceuticals CO., LTD. | Novel Coronavirus Pneumonia (COVID-19) | | | | |
ChiCTR2000031734: Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial |
|
|
| Recruiting | N/A | 40 | | Danoprevir sodium tablets,/ritonavir oral | Huoshenshan Hospital; Huoshenshan Hospital, Ascletis Pharmaceuticals CO., LTD. | Novel Coronavirus Pneumonia (COVID-19) | | | | |
ChiCTR2000030472: An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) |
|
|
| Recruiting | N/A | 20 | | Ganovo/ ritonavir oral+conventional treatment ;Conventional treatment | Shenyang Sixth People's Hospita; Shenyang Sixth People's Hospital, Government | Novel Coronavirus Pneumonia (COVID-19) | | | | |
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C |
|
|
| Recruiting | N/A | 300 | RoW | Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir | Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd | Hepatitis C, Chronic | 07/21 | 08/21 | | |
| paritaprevir/ritonavir (ABT-450/r) / AbbVie |
NCT02460133: Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment |
|
|
| Active, not recruiting | 4 | 44 | NA | Paritaprevir, Ritonavir, Dasabuvir, Ombitasvir, Ribavirin | Nova Scotia Health Authority, Provincial Correction Centre (PEI) | Hepatitis C Virus | 10/25 | 10/25 | | |
| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe |
2011-005636-26: Study about human defence for chronic hepatitis C in patients who will be treated with telaprevir with peginterferon-alfa and ribavirin |
|
|
| Ongoing | 4 | 25 | Europe | Incivo, Incivo | Foundation for Liver Research, Janssen-Cilag | Chronic hepatitis C | | | | |
2012-005525-75: Peg-IFN, RBV and telaprevir vs Peg-IFN and RBV alone in patients with acute hepatitis C and HIV co-infection |
|
|
| Ongoing | 3 | 20 | Europe | Incivo (telaprevir), Incivo, Incivo | St Stephen\'s AIDS Trust, St Stephen's AIDS Trust | Acute hepatitis C infection | | | | |
| Ongoing | 2 | 16 | Europe | Film-coated tablet, Incivo, Paroxetine Sandoz | Radboud University Nijmegen Medical Centre, Janssen Cilag | chronic hepatitis C infection with depression, chronic hepatitis C infection with depression, Diseases [C] - Virus Diseases [C02] | | | | |
2010-021156-26: A Phase 1, Randomized, Open-label, Single-Dose, Crossover, Relative Bioavailability, and Food-Effect Study of a Pediatric Chewable Tablet Formulation Relative to a 375-mg Core Tablet Formulation of Telaprevir in Healthy Adult Subjects |
|
|
| | 1 | | NA | telaprevir, VX-950, | Vertex Pharmaceuticals Inc., Vertex Pharmaceuticals Inc. | chronic hepatitis c virus genotype 1 infection | | | | |
| No Longer Available | N/A | | Europe, RoW | Telaprevir + peginterferon alfa + ribavirin, experimental, peginterferon alfa + ribavirin | Janssen-Cilag International NV | Hepatitis C | | | | |
|
|
|
|
|
|
|
|
|
| Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie |
2016-003607-59: An Open-Label Study to Evaluate Long-Term Results With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) on ovarian function in fertile women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection. Studio in aperto per valutare i risultati a lungo termine con Ombitasvir-paritaprevir-Ritonavir e Dasabuvir, con o senza ribavirina (RBV) sulla funzione ovarica delle donne in et¿ fertile con epatite cronica HCV-positiva, genotipo 1 e 4 . |
|
|
| Not yet recruiting | 4 | 50 | Europe | VIEKIRAX, EXVIERA, 043841, Film-coated tablet, VIEKIRAX - 12,5MG/75MG/50MG COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PE/PCTFE/ALU) - 56 COMPRESSE (CONFEZIONE MULTIPLA), EXVIERA - 250 MG COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PE/PCTFE/ALU) - 56 COMPRESSE (CONFEZIONE MULTIPLA) | DIPARTIMENTO AD ATTIVITà INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE, ABBVIE SRL | Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Epatite cronica HCV-positiva, genotipo 1 e 4, Hepatitis C EPATITE C, Diseases [C] - Virus Diseases [C02] | | | | |
2014-002962-57: Hepatitis C meggyógyítása, cryoglobunaemia és szövödményeinek (vaculitis, neuritis) megszüntetése |
|
|
| Ongoing | 3 | 1 | Europe | ABT-450/r/ABT-267; ABT333 | Egyesített Szent István és Szent László Kórház - Rendelőintézet | | | | | |
2014-004111-37: Individual Patient Access to AbbVie ABT-450/rítonavir/ABT-267 and ABT333 Coadministered witb Ribavirín (RBV) in Patient with Genotype 1 Hepatitis C VírusInfection witb Cirrhosis |
|
|
| Ongoing | 3 | 1 | Europe | ABT-450/r/ABT-267+ABT-333 | BUDAI HEPATOLÓGIAI CENTRUM | | | | | |
2014-004268-38: Individual Patient Access to AbbVie ABT-450/ritopnavir/ABT-267 and ABT-333 Coadministeres with ribavirin (RBV) in Adult Liver Transplant Recipient with Genotype 1 Hepatitis C Virus Infection |
|
|
| Ongoing | 3 | 1 | Europe | ABT-450/ritonavir/ABT-267, ABT-333, | Semmelweis Egyetem Transzplantációs és Sebészeti Klinika | | | | | |
| Ongoing | 2 | 408 | Europe | Viekirax, Exviera (Dasabuvir), Harvoni, Ribavirin (film-coated 200mg), Ribavirin (hard capsule, 200mg), Ribavirin (film-coated, 400mg), Maviret, Film-coated tablet, , Viekirax, Exviera (Dasabuvir), Harvoni, Maviret | Imperial College London, NIHR Efficacy and Mechanism Evaluation Programme | Hepatitis C Infection (HCV) (genotype 1a/1b/4), Hepatitis C infection, Diseases [C] - Virus Diseases [C02] | | | | |
| INO-8000 / Inovio |
NCT02419079: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection |
|
|
| Not yet recruiting | 1/2 | 116 | US | DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Placebo, placebo, placebo therapy, PLCB, sham therapy, Quality-of-Life Assessment, Quality of Life Assessment | National Cancer Institute (NCI) | Chronic Hepatitis, Hepatitis C Infection | 10/17 | | | |
NCT02822079: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection |
|
|
| Recruiting | 1 | 32 | US | DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment | Mayo Clinic, Inovio Pharmaceuticals, National Cancer Institute (NCI) | Chronic Hepatitis, Hepatitis C Infection | 03/20 | | | |
NCT02772003: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection |
|
|
| Active, not recruiting | 1 | 33 | US | Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Rocakinogene Sifuplasmid, DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012 | National Cancer Institute (NCI), Inovio Pharmaceuticals | Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma | 03/20 | 03/25 | | |
| glecaprevir (ABT-493) / AbbVie |
NCT04017338: Transplantation Using Hepatitis C Positive Donors, A Safety Trial |
|
|
| Recruiting | 3 | 40 | Canada | Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Maviret, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion, Normothermic EVLP | Jordan Feld, University Health Network, Toronto | Lung Transplant Infection, Heart Transplant Infection, Kidney Transplant Infection, Kidney Pancreas Infection, Hepatitis C | 12/20 | 12/24 | | |
| Recruiting | N/A | 50 | US | glecaprevir/pibrentasivir | Sentara Norfolk General Hospital | Coronary Artery Disease, Morality | 12/24 | 12/24 | | |
| Zepatier (grazoprevir/elbasvir) / Merck (MSD) |
ACTRN12620000794909: An efficacy study of combined oral doses of glecaprevir/pibrentasvir and sofosbuvir for 16 weeks in hepatitis C patients with documented NS5A resistance who did not respond to previous treatment |
|
|
| Not yet recruiting | 4 | 75 | | | Auckland District Health Board, Auckland District Health Board | Hepatitis C | | | | |
| Not yet recruiting | 4 | 150 | Europe | Zepatier, Film-coated tablet, Zepatier | Kings College Hospital NHS Foundation Trust, Merck, Sharpe and Dohme | hepatitis C viral infection, hepatitis C infection (HCV), Diseases [C] - Virus Diseases [C02] | | | | |
CHROME, NCT03823911: Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication |
|
|
| Completed | 4 | 87 | US | Elbasvir / Grazoprevir Oral Tablet [Zepatier], Sofosbuvir/Ledipasvir, Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir, Cardiac MRI | University of Maryland, Baltimore, National Institutes of Health (NIH), Merck Sharp & Dohme LLC | Cardiovascular Diseases, Hepatitis C, Hiv | 12/22 | 12/22 | | |
2017-003710-58: 8 weeks of Elbasvir/Grazoprevir in patients with Hepatitis C Elbasvir/Grazoprevir per 8 settimane nei pazienti con epatite C |
|
|
| Not yet recruiting | 3 | 75 | Europe | Zepatier, Tablet, ZEPATIER - 50 MG/100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (ALL/ALL)- 28 COMPRESSE | AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO, Merck Sharp & Dohme | chronic hepatitis C epatite cronica da HCV, chronic hepatitis C epatite cronica da HCV, Diseases [C] - Digestive System Diseases [C06] | | | | |
2016-001125-13: Study assessing the efficacy and tolerability of a new oral treatment containing grazoprevir (100mg) and elbasvir (50mg) used during 8 weeks in patients presenting acute hepatitis C (genotypes 1 or 4) and co-infected with human immunodeficiency virus (HIV). Etude évaluant l'efficacité et la tolérance d'un nouveau traitement oral contenant du grazoprevir (100mg) and elbasvir (50mg), utilisé pendant 8 semaines chez des patients présentant une hépatite C aigue (génotypes 1 ou 4) et co-infectés par le virus de l’immunodéficience humaine (VIH). |
|
|
| Ongoing | 2 | 50 | Europe | ZEPATIER, GRAZOPREVIR, ELBASVIR, Tablet, ZEPATIER | IMEA (Institut de Médecine et d’Epidémiologie Appliquée)–Fondation Léon M’Ba, MSD | Acute hepatitis C (genotypes 1 or 4) Hépatite C aigue (génotypes 1 ou 4), Acute hepatitis C (genotypes 1 or 4) Hépatite C aigue (génotypes 1 ou 4), Diseases [C] - Virus Diseases [C02] | | | | |
NCT02940496: Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer |
|
|
| Completed | 2 | 12 | US | Elbasvir/Grazoprevir, Zepatier (BR); Elbasvir-Grazoprevir (SY); Grazoprevir/Elbasvir (SY); Grazoprevir-Elbasvir (SY); MK-8742/ MK-5172 (CN), Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ribavirin, 1-.beta.-D-Ribofuranosyl-1H-1,2, 4-triazole-3-carboxamide, Copegus, ICN 1229, ICN-1229, Rebetol, RIBA, RTCA, Viramide, Virazid, Virazole | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7 | 08/23 | 08/23 | | |
| Completed | 1/2 | 10 | US | Zepatier, Epclusa | University of Pennsylvania, Merck Sharp & Dohme LLC | Lung Diseases | 12/21 | 12/22 | | |
| Completed | 1/2 | 62 | US | Zepatier, Mavyret | University of Pennsylvania, Merck Sharp & Dohme LLC | End Stage Renal Disease | 03/22 | 12/22 | | |
| Recruiting | N/A | 300 | Europe | Elbasvir / Grazoprevir Oral Tablet, sofosbuvir, ledipasvir | University Hospital, Akershus | Hepatitis C, Substance Use Disorders | 10/19 | 12/22 | | |
ChiCTR2000032528: Efficacy and Safety of Elbasvir/Grazoprevir Treatment in Chinese Patients with Hepatitis C Virus Genotype 1b: A Retrospective Study |
|
|
| Completed | N/A | 94 | | Elbavegravir was administered orally, one tablet at a time, once a day, for 12 weeks | The Second Affiliated Hospital of Lanzhou University; The Second Hospital of Lanzhou University, No | Viral hepatitis c | | | | |
ChiCTR2000034389: Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in end-stage renal disease patients undergoing hemodialysis: a retrospective study based on medical records |
|
|
| Not yet recruiting | N/A | 80 | | GZR/EBR | The Second Hospital of Nanjing; The Second Hospital of Nanjing, the second hospital of nanjing | hepatitis C | | | | |
| Completed | N/A | 25 | US | Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER], Zepatier | University of Illinois at Chicago, Merck Sharp & Dohme LLC | Hepatitis C, Hiv, Coinfection, HIV, Substance Use Disorders | 06/22 | 09/22 | | |
ChiCTR1900027793: Two direct antiviral drugs in the clinical effect of reverse c liver fibrosis multicenter prospectie cohort study |
|
|
| Not yet recruiting | N/A | 280 | | Grazoprevir/elbasvir ;Sofosbuvir and velpatasvir | Department of Gastroenterology, Xinqiao Hospital, Affiliated to Military Medical University; Xinqiao Hospital of Army Military University, Self-raised | Chronic hepatitis c | | | | |
| Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma |
2017-002008-28: A prospective open label study to evaluate treatment of chronic HCV infection with glecaprevir/pibrentasvir in PWID attending a needle exchange program |
|
|
| Ongoing | 4 | 50 | Europe | Maviret 100 mg/40 mg tablets, Tablet, Maviret 100 mg/40 mg filmdragerade tabletter glekaprevir/pibrentasvir Maviret 100 mg/40 mg film-coated tablets | Region Skåne, Region Skane | Patients with chronic hepatitis C and without somatic and/or psychiatric contraindications to treatment will be offered participation in the study in a chronological inclusion procedure., Diseases [C] - Virus Diseases [C02] | | | | |
2017-005179-21: Four weeks treatment for chronic hepatitis C in patients under 50 years of age with no significant liver fibrosis Fire ugers behandling af kronisk leverbetændelse type C hos personer under 50 år, uden betydende arvæv i leveren |
|
|
| Ongoing | 4 | 200 | Europe | Maviret, Moderiba, J05AX, J05AB04, Tablet, Maviret, Moderiba | Department of infectious Diseases, Odense University Hospital, Danish regions | Chronic Hepatitis C Kronisk hepatitis C, Chronic Hepatitis C Kronisk leverbetændelse type C, Diseases [C] - Virus Diseases [C02] | | | | |
STRIVE-4, NCT03855917: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir |
|
|
| Recruiting | 4 | 30 | RoW | Sofosbuvir 400mg [Sovaldi], Sovaldi, Glecaprevir/pibrentasvir (300mg/120mg), Maviret | Kirby Institute | Hepatitis C | 02/26 | 02/26 | | |
QUICK-CURE, NCT04515797: QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir |
|
|
| Terminated | 4 | 2 | US | Glecaprevir and Pibrentasvir, Direct Acting Antiviral HCV Treatment, Mavyret | Massachusetts General Hospital | Kidney Failure, Hepatitis C, Kidney Disease, Chronic | 08/23 | 08/23 | | |
NCT04575896: Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors |
|
|
| Completed | 4 | 10 | US | Glecaprevir/pibrentasvir, Mavyret | Johns Hopkins University | End Stage Renal Disease, Hepatitis C | 11/23 | 12/23 | | |
NCT04508907: A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients |
|
|
| Recruiting | 4 | 200 | US | Mavyret, Zetia | Mayo Clinic | Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection | 12/24 | 12/24 | | |
NCT05582681: HCV Test and Treat Utilizing Simplified HCV Patient Education |
|
|
| Recruiting | 4 | 200 | US | Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir, G/P | Weill Medical College of Cornell University, AbbVie | Hepatitis C | 10/27 | 10/27 | | |
2017-002221-37: Six weeks of Glecaprevir/ pibrentasvir for patients with acute HCV infection. Sei settimane di terapia con Glecaprevir/ pibrentasvir per i pazienti con epatite acuta da HCV. |
|
|
| Not yet recruiting | 3/4 | 50 | Europe | Glecaprevir/Pibrentasvir, [Glecaprevir/Pibrentasvir], Film-coated tablet, MAVIRET n.AIC 045445018/E | AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO, Abbvie | Acute HCV infection Epatite acuta da HCV, Acute HCV infection Epatite acuta da HCV, Diseases [C] - Virus Diseases [C02] | | | | |
2017-000694-37: A study to evaluate how effective and safe a simplified treatment monitoring strategy is when applied to people with chronic hepatitis C virus infection without liver disease and taking glecaprevir/pibrentasvir for 8 weeks |
|
|
| Not yet recruiting | 3 | 375 | Europe | glecaprevir/pibrentasvir, ABT-493/ABT-530, Film-coated tablet | University of New South Wales Sydney, Abbvie Pty Ltd, University of New South Wales Sydney | Chronic hepatitis C virus infection, Chronic hepatitis C infection is infection with hepatitis C virus for more than 6 months, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) |
|
|
| Completed | 3 | 286 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret | AbbVie | Hepatitis C Virus (HCV) | 09/24 | 09/24 | | |
NCT05446857: Glecaprevir/Pibrentasvir for the Treatment of PTSD |
|
|
| Completed | 2/3 | 10 | US | Glecaprevir / Pibrentasvir Pill, Mavyret | White River Junction Veterans Affairs Medical Center | PTSD | 04/24 | 04/24 | | |
NCT05637879: Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder |
|
|
| Not yet recruiting | 2/3 | 92 | US | Glecaprevir/pibrentasvir, Mavyret, Placebo | White River Junction Veterans Affairs Medical Center | PTSD | 12/25 | 09/26 | | |
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
|
|
| Completed | 2 | 45 | US, RoW | Glecaprevir/Pibrentasvir (G/P), Mavyret | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C Infection, HIV Infection | 05/23 | 08/23 | | |
NCT04682509: A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation |
|
|
| Completed | 1 | 20 | US | Glecaprevir/pibrentasvir, Mavyret | NYU Langone Health | ESRD | 05/23 | 02/24 | | |
SCALE-C, NCT03776760: Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination |
|
|
| Recruiting | N/A | 600 | RoW | Fingerstick GeneXpert HCV RNA quantitative assay, sofosbuvir/velpatesvir, Epclusa, glecaprevir/pibrentasvir, Maviret | Kirby Institute, South Australian Health and Medical Research Institute, Flinders University | Hepatitis C, Hepatitis, Liver Diseases, Hepatitis, Viral, Human, RNA Virus Infections, Digestive System Diseases | 08/22 | 08/22 | | |
TOPIC, NCT03981211: Treatment of HOsPitalised Inpatients for Hepatitis C (): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs |
|
|
| Recruiting | N/A | 60 | RoW | Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet, Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet | Kirby Institute | Hepatitis C, Liver Inflammation, Liver Cirrhoses | 02/25 | 02/25 | | |
| Completed | N/A | 17 | US | Suboxone, Buprenorphine Naloxone, Truvada, Pre-Exposure Prophylaxis (PrEP), Mavyret, Hepatitis C treatment | Duke University, Center for AIDS Research (CFAR), National Institute of Allergy and Infectious Diseases (NIAID) | Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C | 03/23 | 03/23 | | |
Maviret PMS, NCT03740230: An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs |
|
|
| Completed | N/A | 3134 | RoW | | AbbVie | Hepatitis C | 07/23 | 07/23 | | |
NeoVie, NCT04366973: A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers |
|
|
| Completed | N/A | 95 | Europe | | AbbVie | Hepatitis C Virus (HCV) | 12/23 | 12/23 | | |
NCT06367465: Feasibility and Acceptability of HCV Treatment in Pregnancy |
|
|
| Recruiting | N/A | 50 | US | Glecaprevir-pibrentasvir | Washington University School of Medicine | Hepatitis C, Pregnancy Complications | 02/26 | 02/26 | | |
NCT04214028: A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus |
|
|
| Completed | N/A | 50 | Japan | | AbbVie | Hepatitis C Virus (HCV) | 08/24 | 08/24 | | |
| JNJ-4178 / J&J |
| No trials found |
